Terms: = Leukemia AND NF1, NFNS, 4763, ENSG00000196712, P21359
281 results:
1. Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Feng J; Fei Y; Gao M; Meng X; Zeng D; Zou D; Ye H; Liang Y; Sun X; Liang R; Zhou H; Wang X; Zhang H
Hematol Oncol; 2024 May; 42(3):e3268. PubMed ID: 38676394
[TBL] [Abstract] [Full Text] [Related]
2. Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion.
Ma J; Liu YC; Voss RK; Ma J; Palagani A; Caldwell E; Rosikiewicz W; Cardenas M; Foy S; Umeda M; Wilkinson MR; Inaba H; Klco JM; Rubnitz JE; Wang L
Leukemia; 2024 May; 38(5):981-990. PubMed ID: 38429501
[TBL] [Abstract] [Full Text] [Related]
3. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic leukemia: Focus on the Genes Involved.
Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
[TBL] [Abstract] [Full Text] [Related]
4. Biallelic inactivation of the nf1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
Ramamoorthy S; Lebrecht D; Schanze D; Schanze I; Wieland I; Andrieux G; Metzger P; Hess M; Albert MH; Borkhardt A; Bresters D; Buechner J; Catala A; De Haas V; Dworzak M; Erlacher M; Hasle H; Jahnukainen K; Locatelli F; Masetti R; Stary J; Turkiewicz D; Vinci L; Wlodarski MW; Yoshimi A; Boerries M; Niemeyer CM; Zenker M; Flotho C
Br J Haematol; 2024 Feb; 204(2):595-605. PubMed ID: 37945316
[TBL] [Abstract] [Full Text] [Related]
5.
Giraud JS; Bièche I; Pasmant É; Tlemsani C
Expert Opin Investig Drugs; 2023; 32(10):941-957. PubMed ID: 37747491
[TBL] [Abstract] [Full Text] [Related]
6. Assessment of Ecotropic Viral Integration Site 2B (EVI2B) Gene in Juvenile Myelomonocytic leukemia and Neurofibromatosis Type 1 nf1 Tumors.
Saharafi P; Akar İ; Ersoy-Evans S; Anlar B; Varan A; Vargel I; Cetin M; Ayter S
Biochem Genet; 2024 Apr; 62(2):1263-1276. PubMed ID: 37584733
[TBL] [Abstract] [Full Text] [Related]
7. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract] [Full Text] [Related]
8. Neurocutaneous Syndromes, Perinatal Factors, and the Risk of Childhood Cancer in Sweden.
Kampitsi CE; Nordgren A; Mogensen H; Pontén E; Feychting M; Tettamanti G
JAMA Netw Open; 2023 Jul; 6(7):e2325482. PubMed ID: 37490289
[TBL] [Abstract] [Full Text] [Related]
9. Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
Calabresi L; Carretta C; Romagnoli S; Rotunno G; Parenti S; Bertesi M; Bartalucci N; Rontauroli S; Chiereghin C; Castellano S; Gentili G; Maccari C; Vanderwert F; Mannelli F; Della Porta M; Manfredini R; Vannucchi AM; Guglielmelli P
Am J Hematol; 2023 Oct; 98(10):1520-1531. PubMed ID: 37399248
[TBL] [Abstract] [Full Text] [Related]
10. [Pheochromocytoma associated with primary hyperparathyroidism and type 1 neurofibromatosis].
Ryabchenko EV; Dremlyuga NV; Mezhinskaya EM; Polyansky EA
Khirurgiia (Mosk); 2023; (7):120-127. PubMed ID: 37379415
[TBL] [Abstract] [Full Text] [Related]
11. Genomic landscape of TP53-mutated myeloid malignancies.
Abel HJ; Oetjen KA; Miller CA; Ramakrishnan SM; Day RB; Helton NM; Fronick CC; Fulton RS; Heath SE; Tarnawsky SP; Nonavinkere Srivatsan S; Duncavage EJ; Schroeder MC; Payton JE; Spencer DH; Walter MJ; Westervelt P; DiPersio JF; Ley TJ; Link DC
Blood Adv; 2023 Aug; 7(16):4586-4598. PubMed ID: 37339484
[TBL] [Abstract] [Full Text] [Related]
12. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
[TBL] [Abstract] [Full Text] [Related]
13. Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea.
Yun J; Song H; Kim SM; Kim S; Kwon SR; Lee YE; Jeong D; Park JH; Kwon S; Yun H; Lee DS
Hum Genomics; 2023 Feb; 17(1):13. PubMed ID: 36814285
[TBL] [Abstract] [Full Text] [Related]
14. Synchronous cutaneous malignant peripheral nerve sheath tumor and jejunal gastrointestinal stromal tumor and submucosal angiomyolipoma in type 1 neurofibromatosis: A case report and literature review.
Kim KJ; Kim MS; Hong R; Lim SC
Medicine (Baltimore); 2023 Jan; 102(3):e32696. PubMed ID: 36701730
[TBL] [Abstract] [Full Text] [Related]
15. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
[TBL] [Abstract] [Full Text] [Related]
16. Novel Germline
Provenzano A; Chetta M; De Filpo G; Cantini G; La Barbera A; Nesi G; Santi R; Martinelli S; Rapizzi E; Luconi M; Maggi M; Mannelli M; Ercolino T; Canu L
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013579
[TBL] [Abstract] [Full Text] [Related]
17. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.
Kumari S; Ali MS; Singh J; Arora M; Verma D; Pandey AK; Benjamin M; Bakhshi S; Palanichamy JK; Sharma A; Singh I; Tanwar P; Singh AR; Pushpam D; Qamar I; Chopra A
Hematol Oncol; 2022 Oct; 40(4):577-587. PubMed ID: 35644022
[TBL] [Abstract] [Full Text] [Related]
19. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Tashakori M; Kadia T; Loghavi S; Daver N; Kanagal-Shamanna R; Pierce S; Sui D; Wei P; Khodakarami F; Tang Z; Routbort M; Bivins CA; Jabbour EJ; Medeiros LJ; Bhalla K; Kantarjian HM; Ravandi F; Khoury JD
Blood; 2022 Jul; 140(1):58-72. PubMed ID: 35390143
[TBL] [Abstract] [Full Text] [Related]
20. RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.
Decroocq J; Birsen R; Montersino C; Chaskar P; Mano J; Poulain L; Friedrich C; Alary AS; Guermouche H; Sahal A; Fouquet G; Gotanègre M; Simonetta F; Mouche S; Gestraud P; Lescure A; Del Nery E; Bosc C; Grenier A; Mazed F; Mondesir J; Chapuis N; Ho L; Boughalem A; Lelorc'h M; Gobeaux C; Fontenay M; Recher C; Vey N; Guillé A; Birnbaum D; Hermine O; Radford-Weiss I; Tsantoulis P; Collette Y; Castellano R; Sarry JE; Pasmant E; Bouscary D; Kosmider O; Tamburini J
Leukemia; 2022 May; 36(5):1237-1252. PubMed ID: 35354920
[TBL] [Abstract] [Full Text] [Related]
[Next]
